Cancer

Stanford Medicine’s new proton therapy facility is ready for patients. On June 4 a child with a rare brain tumor became the first to receive treatment.

Research indicates that changes to Medicaid’s retroactive eligibility may leave newly diagnosed gastrointestinal cancer patients facing substantial, unanticipated medical expenses.

A new study shows how a noninvasive blood test can identify nine tumor neighborhoods, predicting microenvironments that affect patient responses to immunotherapy.

A $10 million commitment aims to help the American Cancer Society build a new Hope Lodge, providing temporary lodging for cancer patients traveling to the Bay Area for treatment.

Radiation oncology Professor Billy Loo discusses the recent opening of a first-of-its-kind proton therapy machine for cancer treatment at the Stanford Medicine Cancer Center.

The center is the first in the world to introduce ultracompact proton therapy, making advanced targeted radiotherapy more accessible to pediatric and adult patients.

Immune cells engineered to sense metabolic byproducts secreted by cancer cells “follow their noses” to migrate to and infiltrate solid tumors in mice in a Stanford Medicine study.

The earliest sign of bladder cancer – blood in the urine – is often invisible to people who are colorblind, increasing their risk of dying from the disease.

Antibody-lectin chimeras may block cancer cell defenses, improving the immune system’s ability to target tumors. Chemist Carolyn Bertozzi discusses their potential to help more patients.

A key molecule involved in red blood cell production governs whether the immune system attacks or tolerates cells.